SRI Biosciences is ideally positioned as your single-source partner to seamlessly integrate basic research, drug and diagnostic discovery, and nonclinical and clinical development. We are committed to helping you achieve your goals—from lead identification through the Investigational New Drug application (IND) and into human clinical trials.
Basic Research

Decades of fundamental research experience in disease mechanisms make SRI an ideal partner to solve your most difficult problems in drug development. We have made breakthroughs that are saving lives today.

Drug & Diagnostics Discovery and Development

SRI is creating new technology platforms for new generations of drug and diagnostics discovery and development. SRI's success is exemplified by our robust pipeline of marketed drugs, products in clinical and preclinical development, and programs in discovery.

Contract R & D Services

SRI offers comprehensive contract R&D services for drugs, biologics, devices and diagnostics discovery and development. Outsourcing to SRI maximizes your investment dollars while minimizing risk.
Basic Research

Cancer

Infectious Disease

Neuroscience

Immunology
Drug Discovery

Target Discovery, Validation & Assay Development
- Cell-Based Assays
- Mechanism-Based Animal Models
- Design and Validation of Biochemical and Cellular Screens
- Proteomics
- Expression Analysis
- Imaging (including MRI) and Analysis
- Rare Cell Detection-Based Assays

Lead Identification & Optimization
- Screening Hits to Leads
- Medicinal Chemistry
- Structure Activity Relationships (SAR)
- Computational Chemistry and Structure-Based Design
- Lead Optimization
- Mechanism-of-Action Studies
- Metabolite Standard Synthesis

Pharmacology, Efficacy & Predictive ADMET
- In Vitro and In Vivo Efficacy
- Translational Animal Models
- Predictive ADMET Assays
- Radiolabeled Synthesis
- Synthesis and Scale-Up
- Preformulation
- Biomarkers
- CTC Diagnostics
Nonclinical Development

<table>
<thead>
<tr>
<th>Safety, Drug Metabolism &amp; Pharmacokinetics</th>
<th>Chemistry, Manufacturing &amp; Controls, Regulatory Support</th>
</tr>
</thead>
<tbody>
<tr>
<td>Range-Finding Toxicity</td>
<td>Dosage Form Development</td>
</tr>
<tr>
<td>Pharmacokinetics</td>
<td>Analytical Method Development and Validation</td>
</tr>
<tr>
<td>Bioavailability and ADME</td>
<td>cGMP Clinical Trial Materials (Investigational Product)</td>
</tr>
<tr>
<td>Biodistribution</td>
<td>Stability and Release Testing</td>
</tr>
<tr>
<td>GLP Toxicology (All Major Species)</td>
<td>Project Management</td>
</tr>
<tr>
<td>Mammalian Toxicology</td>
<td>Quality Assurance</td>
</tr>
<tr>
<td>Safety Pharmacology</td>
<td></td>
</tr>
<tr>
<td>Radiation Biology</td>
<td></td>
</tr>
<tr>
<td>Genetic Toxicology</td>
<td></td>
</tr>
<tr>
<td>Reproductive Toxicology</td>
<td></td>
</tr>
<tr>
<td>Immunotoxicology</td>
<td></td>
</tr>
<tr>
<td>Immunogenicity</td>
<td></td>
</tr>
<tr>
<td>Clinical Laboratory Services</td>
<td></td>
</tr>
<tr>
<td>Toxicogenomics and Biomarkers</td>
<td></td>
</tr>
</tbody>
</table>

SRI Drug Discovery & Nonclinical Development Capabilities
Clinical Development

**SRI PIPELINE**

- Oral DTPA
  - Radionuclide Decorporation Agent

- SR16234 (TAS-108)
  - Endometriosis

**Marketed SRI Drugs**

- Bexarotene
  - Cutaneous T-Cell Lymphoma

- Halofantrine
  - Antimalarial

- Pralatrexate
  - Peripheral T-Cell Lymphoma

- Vidarabine
  - Antiviral

---

**SRI Clinical Trial Services**

- Clinical trial design, conduct, data analysis and reporting
- Safety determination, tolerability, PK/PD, dose-ranging, bio-equivalence, drug-drug interaction, and food effects in healthy volunteers
- Efficacy evaluation and side effects determination in patient volunteers

---

**Clinical Development**

<table>
<thead>
<tr>
<th>PHASE 1</th>
<th>PHASE 2</th>
<th>PHASE 3</th>
<th>PHASE 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Safety/PK</td>
<td>Evaluate efficacy</td>
<td>Confirm efficacy</td>
<td>Post-marketing</td>
</tr>
</tbody>
</table>
Your strategic resource.

SRI’s clients and partners benefit from the multidisciplinary expertise of our research staff and strict adherence to regulatory guidelines. We partner with pharmaceutical and biotech companies, government agencies, foundations, and academic organizations around the world to provide research and services that span all stages of drug discovery, nonclinical development, and early human clinical trials.

Your goals are our top priority. SRI provides outstanding customer service combined with a commitment to scientific excellence through best-in-class research and development.

Quality. Value. Results.
We understand the pressures of a highly competitive market. Our expertise, state-of-the-art facilities, and advanced technologies will help you accelerate along the product development continuum. Count on SRI for cost-effective drug discovery and preclinical development results. You can depend on us to get it right the first time.

Passion. Commitment. Leadership.
At SRI, we believe in making a difference. Our professional teams provide unparalleled expertise in developing innovative solutions that meet your specific needs. Backed by decades of experience, we will confront your biggest challenges and exceed your highest expectations.
About SRI Biosciences

SRI’s Biosciences Division carries out basic research, drug and diagnostics discovery and development, and provides R&D contract services. SRI has all the resources necessary to take R&D from Idea to IND and Beyond™ - from initial discovery to human clinical trials - and specializes in cancer, immunology and inflammation, infectious disease, and neuroscience. SRI’s product pipeline has yielded marketed drugs, therapeutics currently in clinical trials, and additional programs in earlier stages. In its CRO business, SRI has helped government and other clients and partners advance well over 100 drugs into patient testing. SRI is also working to create the next generation of technologies in areas such as diagnostics, drug delivery, medical devices, and systems biology.

www.sri.com/biosciences